Context Therapeutics
CNTX
CNTX
59 hedge funds and large institutions have $206M invested in Context Therapeutics in 2026 Q1 according to their latest regulatory filings, with 25 funds opening new positions, 10 increasing their positions, 13 reducing their positions, and 7 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding in top 10
Funds holding in top 10: →
more capital invested
Capital invested by funds: $ → $
more funds holding
Funds holding: →
15.2% more ownership
Funds ownership: 70.98% → 86.17% (+15%)
23% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 13
51% less call options, than puts
Call options by funds: $53K | Put options by funds: $108K
Holders
59
Holding in Top 10
3
Calls
$53K
Puts
$108K
Top Buyers
| 1 | +$16.3M | |
| 2 | +$12.3M | |
| 3 | +$10.5M | |
| 4 |
TCM
TCG Crossover Management
Palo Alto,
California
|
+$6.26M |
| 5 |
SCM
Squadron Capital Management
Westmont,
Illinois
|
+$2.57M |
Top Sellers
| 1 | -$5.71M | |
| 2 | -$5.47M | |
| 3 | -$3.59M | |
| 4 |
Millennium Management
New York
|
-$2.75M |
| 5 |
Alyeska Investment Group
Chicago,
Illinois
|
-$2.45M |
